287 related articles for article (PubMed ID: 10472344)
41. Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients.
Dunst J; Semlin S; Pigorsch S; Müller AC; Reese T
Strahlenther Onkol; 2000 Sep; 176(9):416-21. PubMed ID: 11050915
[TBL] [Abstract][Full Text] [Related]
42. Improved tolerability of amifostine with rapid infusion and optimal patient preparation.
Boccia R
Semin Oncol; 2002 Dec; 29(6 Suppl 19):9-13. PubMed ID: 12577237
[TBL] [Abstract][Full Text] [Related]
43. Comment on: 'Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients' Radiother Oncol 70: 261-264, 2004 by Dr Rades et al.
Cengiz M; Onal C; Yildiz F; Zorlu AF
Radiother Oncol; 2004 Oct; 73(1):109; author reply 109-10. PubMed ID: 15465155
[No Abstract] [Full Text] [Related]
44. A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity.
Kouloulias VE; Kouvaris JR; Pissakas G; Kokakis JD; Antypas C; Mallas E; Matsopoulos G; Michopoulos S; Vosdoganis SP; Kostakopoulos A; Vlahos LJ
Strahlenther Onkol; 2004 Sep; 180(9):557-62. PubMed ID: 15378186
[TBL] [Abstract][Full Text] [Related]
45. The role of amifostine in the treatment of carcinoma of the uterine cervix: an update of RTOG-0116 and review of future directions.
De Los Santos JF; Small W
Semin Oncol; 2004 Dec; 31(6 Suppl 18):37-41. PubMed ID: 15726521
[TBL] [Abstract][Full Text] [Related]
46. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany.
Bennett CL; Lane D; Stinson T; Glatzel M; Buntzel J
Cancer Invest; 2001; 19(2):107-13. PubMed ID: 11296615
[TBL] [Abstract][Full Text] [Related]
47. Moist skin care can diminish acute radiation-induced skin toxicity.
Momm F; Weissenberger C; Bartelt S; Henke M
Strahlenther Onkol; 2003 Oct; 179(10):708-12. PubMed ID: 14566480
[TBL] [Abstract][Full Text] [Related]
48. Hypofractionated and accelerated radiotherapy with subcutaneous amifostine cytoprotection as short adjuvant regimen after breast-conserving surgery: interim report.
Koukourakis MI; Tsoutsou PG; Abatzoglou IM; Sismanidou K; Giatromanolaki A; Sivridis E
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1173-80. PubMed ID: 19058920
[TBL] [Abstract][Full Text] [Related]
49. What should the optimal timing be for amifostine administration relative to radiation and chemotherapy?
Komaki R
J Clin Oncol; 2005 Oct; 23(28):7232-3; author reply 7233-5. PubMed ID: 16192612
[No Abstract] [Full Text] [Related]
50. Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy.
Kouvaris J; Kouloulias V; Malas E; Antypas C; Kokakis J; Michopoulos S; Matsopoulos G; Vlahos L
Strahlenther Onkol; 2003 Mar; 179(3):167-74. PubMed ID: 12627259
[TBL] [Abstract][Full Text] [Related]
51. Amifostine as a radioprotectant.
Gosselin TK; Mautner B
Clin J Oncol Nurs; 2002; 6(3):175-6, 180. PubMed ID: 11998614
[No Abstract] [Full Text] [Related]
52. Amifostine in the treatment of head and neck cancer: intravenous administration, subcutaneous administration, or none of the above.
Eisbruch A
J Clin Oncol; 2011 Jan; 29(2):119-21. PubMed ID: 21115854
[No Abstract] [Full Text] [Related]
53. Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity.
Vujaskovic Z; Feng QF; Rabbani ZN; Samulski TV; Anscher MS; Brizel DM
Exp Lung Res; 2002; 28(7):577-90. PubMed ID: 12396250
[TBL] [Abstract][Full Text] [Related]
54. Influence of amifostine on late radiation-toxicity in head and neck cancer--a follow-up study.
Büntzel J; Glatzel M; Mücke R; Micke O; Bruns F
Anticancer Res; 2007; 27(4A):1953-6. PubMed ID: 17649803
[TBL] [Abstract][Full Text] [Related]
55. [Alteration of radiation-induced hematotoxicity by amifostine (ethyol)].
Momm F; Bechtold C; Fischer K; Tsekos A; Henke M
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():2-5. PubMed ID: 10584132
[TBL] [Abstract][Full Text] [Related]
56. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma.
Amrein PC; Clark JR; Supko JG; Fabian RL; Wang CC; Colevas AD; Posner MR; Deschler DG; Rocco JW; Finkelstein DM; McIntyre JF
Cancer; 2005 Oct; 104(7):1418-27. PubMed ID: 16116597
[TBL] [Abstract][Full Text] [Related]
57. The use of amifostine to prevent xerostomia in patients receiving radiation therapy.
Batcha M
Oncol Nurs Forum; 2000 May; 27(4):615-6. PubMed ID: 10833684
[No Abstract] [Full Text] [Related]
58. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study.
Koukourakis MI; Kyrias G; Kakolyris S; Kouroussis C; Frangiadaki C; Giatromanolaki A; Retalis G; Georgoulias V
J Clin Oncol; 2000 Jun; 18(11):2226-33. PubMed ID: 10829042
[TBL] [Abstract][Full Text] [Related]
59. Can the use of amifostine improve cure rates for patients with advanced non-small cell lung cancer?
Rosenman J
Semin Oncol; 2004 Dec; 31(6 Suppl 18):52-8. PubMed ID: 15726524
[TBL] [Abstract][Full Text] [Related]
60. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
Braaksma M; Levendag P
Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
